<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9508162</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20933</journal-id>
<journal-id journal-id-type="nlm-ta">Inflamm Bowel Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">Inflamm. Bowel Dis.</journal-id>
<journal-title-group>
<journal-title>Inflammatory bowel diseases</journal-title>
</journal-title-group>
<issn pub-type="ppub">1078-0998</issn>
<issn pub-type="epub">1536-4844</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27070911</article-id>
<article-id pub-id-type="pmc">4838534</article-id>
<article-id pub-id-type="doi">10.1097/MIB.0000000000000750</article-id>
<article-id pub-id-type="manuscript">NIHMS751286</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Current understanding of dysbiosis in disease in human and animal models</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>DeGruttola</surname>
<given-names>Arianna K.</given-names>
</name>
<degrees>B.S.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Low</surname>
<given-names>Daren</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mizoguchi</surname>
<given-names>Atsushi</given-names>
</name>
<degrees>M.D., Ph.D.</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mizoguchi</surname>
<given-names>Emiko</given-names>
</name>
<degrees>M.D., Ph.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA</aff>
<aff id="A2"><label>2</label>Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka Japan</aff>
<aff id="A3"><label>3</label>Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA</aff>
<author-notes>
<corresp id="FN1">Correspondence: Emiko Mizoguchi, M.D., Ph.D., Massachusetts General Hospital, GRJ 825D, 55 Fruit Street, Boston, MA 02114, USA, Fax: (617) 726-3673, Phone: (617) 643-1736, <email>emizoguchi@mgh.harvard.edu</email></corresp>
<fn fn-type="conflict" id="FN2">
<p><bold>Conflicts of interest:</bold> The authors have no conflicts of interest to disclose.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>14</day>
<month>1</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>5</month>
<year>2016</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<fpage>1137</fpage>
<lpage>1150</lpage>
<!--elocation-id from pubmed: 10.1097/MIB.0000000000000750-->
<abstract>
<p id="P1">Inflammatory bowel disease (IBD) is an intestinal inflammatory condition that affects over two million people in the United States. Although the etiology and pathogenesis of IBD are still largely unknown, dysregulated host/enteric microbial interactions are requisite for the development of IBD. So far, many researchers have tried to identify a precise relationship between IBD and an imbalance of the intestinal microbiota, termed “dysbiosis”. In spite of the extensive efforts, it is still largely unknown about the interplay among microbes, their hosts, and their environments, and whether dysbiosis is a causal factor or an effect of IBD. Recently, deep-sequencing analyses of the microbiota in IBD patients have been instrumental in characterizing the strong association between dysbiosis and IBD development, although it is still unable to identify specific-associated species level changes in most cases. Based on many recent reports, dysbiosis of the commensal microbiota is implicated in the pathogenesis of several diseases, including IBD, obesity, and allergic disorders, in both human and animal models.</p>
<p id="P2">In this review article, we have focused on explaining the multiple types of dysbiosis, as well as dysbiosis-related diseases and potential treatments in order to apply this knowledge to understand a possible cause and potentially find therapeutic strategies for IBD as well as the other dysbiosis-related diseases.</p>
</abstract>
<kwd-group>
<kwd>Dysbiosis</kwd>
<kwd>Inflammatory Bowel Disease</kwd>
<kwd>Colorectal cancer</kwd>
<kwd>Fecal Microbiota</kwd>
<kwd>IBD-susceptibility genes</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>